- Email: [email protected]
Multiple Pathway Modulating Therapy for Pulmonary Hypertension: A Survey of Practice Patterns and Perceptions
Pulmonary Vascular Disease SESSION TITLE: Pulmonary Vascular Disease II SESSION TYPE: Original Investigation Poster PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
Multiple Pathway Modulating Therapy for Pulmonary Hypertension: A Survey of Practice Patterns and Perceptions Jesslyn Magee BS Andrea Gochi BA; and Vivek Gupta PhD* School of Applied Life Sciences, Keck Graduate Institute, Claremont, CA
PULMONARY VASCULAR DISEASE
PURPOSE: Pulmonary hypertension (PH) is a rare, life-threatening disease that is commonly associated with various comorbidities. Although multiple therapies are approved by FDA in recent years, less than significant improvement is seen in patient survival. A primary reason for suboptimal therapeutic benefits can be attributed to ability of current therapies to merely ameliorate PH symptoms without limiting the vasculopathy associated with disease progression. Due to existence of overlapping and interconnected pathological pathways, PH management has been a cumbersome task as the current therapeutic interventions only target one of the many pathological pathways involved. This study is aimed to evaluate the need for a multiple pathway modulating therapy for PH management. METHODS: To assess the need for multiple pathway modulating therapy, a survey was designed and distributed to PH clinicians and experts. The survey contained a total of 10 questions on a Likert scale of 1-5, and focused on issues surrounding current PH therapies: efficacy, safety, patient compliance and the need for a therapy modulating multiple pathways. Quantitative and qualitative responses were recorded, and the obtained data were analyzed. RESULTS: Preliminary results of the study showed that there was unanimous acceptance among PH healthcare professionals of the need for a therapy modulating multiple pathways (overall numeric response being 5 on a scale of 1-5). Furthermore, the current therapies were only moderately successful in terms of patient compliance (3 on a scale of 1-5). In addition to the issues with patient compliance and need for multiple pathway modulating therapy, it was also discovered that there are tremendous cost implications of PH treatment on payers. Based on preliminary calculations, a new therapy modulating multiple pathogenic pathways will minimize the number of prescription medications and mitigate re-hospitalization occurrences, thus saving each patient upwards of $150,000. CONCLUSIONS: Overall, we found that in consideration of disease outcome and cost burden of PH, there is great potential for a new multiple pathway modulating therapy to be successful in the PH market. CLINICAL IMPLICATIONS: Clinical implications of developing a novel therapy capable of modulating multiple pathogenic pathways responsible for PH pathogenesis will be beneficial in not only advancing the current PH therapeutic regimen but will also have significant benefits in elucidating and exploiting the pathological links between PH and several associated disorders. DISCLOSURE: The following authors have nothing to disclose: Jesslyn Magee, Andrea Gochi, Vivek Gupta No Product/Research Disclosure Information DOI:
http://dx.doi.org/10.1016/j.chest.2016.08.1295
Copyright ª 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
1186A
[
150#4S CHEST OCTOBER 2016
]
Multiple Pathway Modulating Therapy for Pulmonary Hypertension: A Survey of Practice Patterns and Perceptions Jesslyn Magee BS Andrea Gochi BA; and Vivek Gupta PhD* School of Applied Life Sciences, Keck Graduate Institute, Claremont, CA
PULMONARY VASCULAR DISEASE
PURPOSE: Pulmonary hypertension (PH) is a rare, life-threatening disease that is commonly associated with various comorbidities. Although multiple therapies are approved by FDA in recent years, less than significant improvement is seen in patient survival. A primary reason for suboptimal therapeutic benefits can be attributed to ability of current therapies to merely ameliorate PH symptoms without limiting the vasculopathy associated with disease progression. Due to existence of overlapping and interconnected pathological pathways, PH management has been a cumbersome task as the current therapeutic interventions only target one of the many pathological pathways involved. This study is aimed to evaluate the need for a multiple pathway modulating therapy for PH management. METHODS: To assess the need for multiple pathway modulating therapy, a survey was designed and distributed to PH clinicians and experts. The survey contained a total of 10 questions on a Likert scale of 1-5, and focused on issues surrounding current PH therapies: efficacy, safety, patient compliance and the need for a therapy modulating multiple pathways. Quantitative and qualitative responses were recorded, and the obtained data were analyzed. RESULTS: Preliminary results of the study showed that there was unanimous acceptance among PH healthcare professionals of the need for a therapy modulating multiple pathways (overall numeric response being 5 on a scale of 1-5). Furthermore, the current therapies were only moderately successful in terms of patient compliance (3 on a scale of 1-5). In addition to the issues with patient compliance and need for multiple pathway modulating therapy, it was also discovered that there are tremendous cost implications of PH treatment on payers. Based on preliminary calculations, a new therapy modulating multiple pathogenic pathways will minimize the number of prescription medications and mitigate re-hospitalization occurrences, thus saving each patient upwards of $150,000. CONCLUSIONS: Overall, we found that in consideration of disease outcome and cost burden of PH, there is great potential for a new multiple pathway modulating therapy to be successful in the PH market. CLINICAL IMPLICATIONS: Clinical implications of developing a novel therapy capable of modulating multiple pathogenic pathways responsible for PH pathogenesis will be beneficial in not only advancing the current PH therapeutic regimen but will also have significant benefits in elucidating and exploiting the pathological links between PH and several associated disorders. DISCLOSURE: The following authors have nothing to disclose: Jesslyn Magee, Andrea Gochi, Vivek Gupta No Product/Research Disclosure Information DOI:
http://dx.doi.org/10.1016/j.chest.2016.08.1295
Copyright ª 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
1186A
[
150#4S CHEST OCTOBER 2016
]